

Liberia

Support for Vaccine: Typhoid Conjugate Vaccine

This Decision Letter sets out the Programme Terms of a Programme

This Decision Letter forms part of the Partnership Framework Agreement and together with the Partnership Framework Agreement sets out the Programme Terms of the Programme. Any term used in this Decision Letter but not defined shall have the meaning given to such term in the Partnership Framework Agreement. The English language version of this Decision Letter shall prevail in the case of any conflict with terms expressed in any other language.

1. **Country:** Liberia

2. **Vaccine grant number:** LBR-TCV-R

3. **Date of Decision Letter¹:** 29 September 2022

4. **Date of the Partnership Framework Agreement (the "PFA"):** 19 August 2013

5. **Programme title:** New Vaccine Support (NVS), Typhoid Conjugate Vaccine, Routine

6. **Requested product presentation and formulation of vaccine:**

TCV, 5 dose/vial, liquid

7. **Programme duration²:** 2020-2027

8. **Annual Amounts:** (subject to the terms of the PFA)

This is the total amount approved by Gavi for the entire duration of the programme. Annual amounts are defined as per section 4.1 of the PFA. The annual amounts are indicative and not limited for use for the specified year. Any requested adjustments to the Annual Amounts will be subject to Gavi approval. It is essential that Country's Health Sector Coordination Committee (or its equivalent) be involved with this process both in its technical process function and its support during implementation and monitoring of the Programme. Further, amounts are indicative and are subject to the availability of funds and relevant approvals by the Gavi Board.

| | 2020-2022 | 2023 | 2024 | 2025 | 2026 | 2027 | Total |
|-----------------------|-----------|---------|---------|------|------|------|---------|
| Annual Amounts (US\$) | 769.764 | 101.489 | 101.489 | - | - | - | 972.742 |

¹ This Decision Letter will apply for the programme duration. Gavi will only update this Decision Letter in the event of the following: i) release of future year approvals; ii) adjustments to initial quantities; iii) product price changes or product switches; and/or iv) co-financing amounts.

² This is the entire duration of the programme.

9. Vaccine introduction grant:

| Approval | | |
|----------|---------------|---------------|
| Year | Grant number | Amount (US\$) |
| 2020 | LBR-TCV-R-VIG | 155.710 |

10. Product switch grant:

Not applicable

11. Indicative annual amounts: (subject to the terms of the PFA)

| Gavi Support | 2020 - 2022 | 2023 | | 2024 | | 2025 | | 2026 | | 2027 | |
|-----------------------------|----------------|--------|-------------------|--------|-------------------|-------|-------------------|-------|-------------------|-------|-------------------|
| | | Units | Total Cost (US\$) | Units | Total Cost (US\$) | Units | Total Cost (US\$) | Units | Total Cost (US\$) | Units | Total Cost (US\$) |
| TCV, 5 dose/vial, liquid | | 68.200 | 94.798 | 68.200 | 94.798 | - | - | - | - | - | - |
| Syringe, A-D 0.5ml | | 78.800 | 4.421 | 78.800 | 4.421 | - | - | - | - | - | - |
| Safety Box | | 875 | 670 | 875 | 670 | - | - | - | - | - | - |
| Freight costs - doses | | 1 | 1.084 | 1 | 1.084 | - | - | - | - | - | - |
| Freight costs - devices | | 1 | 516 | 1 | 516 | - | - | - | - | - | - |
| Total amounts (US\$) | 769.764 | | 101.489 | | 101.489 | | - | | - | | - |

12. Procurement agency: UNICEF Supply Division. The Country shall release its co-financing payments each year to UNICEF Supply Division.

13. Self-procurement:

Not applicable

14. Co-financing obligations (indicative)³:

| According to the co-financing policy, the Country falls within the group: Initial self-financing | | | | | | | | | | | |
|---|-------|-------------------|-------|-------------------|-------|-------------------|-------|-------------------|-------|-------------------|--|
| Co-Finance Obligation | 2023 | | 2024 | | 2025 | | 2026 | | 2027 | | |
| | Units | Total Cost (US\$) | Units | Total Cost (US\$) | Units | Total Cost (US\$) | Units | Total Cost (US\$) | Units | Total Cost (US\$) | |
| Material | | | | | | | | | | | |

³ Gavi may adjust the outlined co-financing obligations based on the corresponding actual dose shipments to the country. Any over/under co-financed doses/amounts will be settled in subsequent payments.

| | | | | | | | | | | |
|--|--------|---------------|--------|---------------|---|---|---|---|---|---|
| TCV, 5 dose/vial, liquid | 11.350 | 15.777 | 11.350 | 15.777 | - | - | - | - | - | - |
| Freight costs - doses | 1 | 1.776 | 1 | 1.776 | - | - | - | - | - | - |
| Total Co-Financing (\$USD) expected | | 17.553 | | 17.553 | | - | | - | | - |

15. Operational support for campaigns:

Not applicable

16. Additional Reporting Requirements:

| Reports and other information : | Due dates |
|--|------------------------------------|
| To enable the annual release of purchase orders, Country shall report closing stock levels by 31 st March of each calendar year. ⁴ | 31 March |
| In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance. | To be agreed with Gavi Secretariat |

17. Financial clarifications:

Not applicable

18. Other conditions:

Not applicable

For Gavi
Signed by



Colette Selman
Director, Core Countries
29 September 2022

⁴ Reporting requirements are subject to change. Countries may be required to submit quarterly or monthly stock reports. Country will be notified of updated reporting requirements separately.